BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Randomised Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy.
Phase 4
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: PlaceboDrug: Levitra (Vardenafil, BAY38-9456)
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 260
- Registration Number
- NCT00668096
BAY88-8223, Does Response Study in HRPC Patients
Phase 2
Completed
- Conditions
- Hormone Refractory Prostate CancerBone Metastases
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 100
- Registration Number
- NCT00667199
Vardenafil in Tinnitus
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 43
- Registration Number
- NCT00666809
A Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction
Phase 3
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: PlaceboDrug: Levitra (Vardenafil, BAY38-9456)
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 732
- Registration Number
- NCT00665496
Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED)
Phase 4
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: Levitra (Vardenafil, BAY38-9456)Drug: Placebo
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 219
- Registration Number
- NCT00665340
BAY38-9456, 5/10/20mg, vs.Placebo in Erectile Dysfunction
Phase 4
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: Levitra (Vardenafil, BAY38-9456)Drug: Placebo
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 160
- Registration Number
- NCT00665054
Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia
Phase 4
Completed
- Conditions
- Pneumonia
- Interventions
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 401
- Registration Number
- NCT00665327
Evaluation of LEVITRA to Advance the Treatment of Erectile Dysfunction
Phase 4
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Behavioral: Levitra (Vardenafil, BAY38-9456)Other: No Education
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1029
- Registration Number
- NCT00664833
Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and Hyperlipidemia
Phase 4
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: PlaceboDrug: Levitra (Vardenafil, BAY38-9456)
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 395
- Registration Number
- NCT00663845
Sorafenib Gastric Cancer Asian Phase I Study
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2013-06-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 13
- Registration Number
- NCT00663741
Β© Copyright 2025. All Rights Reserved by MedPath